ASH 2022 | Evaluating IPSS-R and IPSS-M in patients with HR-MDS enrolled in STIMULUS-MDS1 and STIMULUS-MDS2
In this video, Valeria Santini, MD, University of Florence, Florence, Italy, discusses disease characteristics of patients with higher-risk myelodysplastic syndromes (HR-MDS) enrolled in the STIMULUS-MDS1 (NCT03946670) and STIMULUS-MDS2 (NCT04266301) trials, and further compares the Revised International Prognostic Scoring System (IPSS-R) to the Molecular International Prognostic Scoring System (IPSS-M) in this patient population. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis, AbbVie, BMS, Gilead, Menarini, Geron, Otsuka: Honoraria.
